OnKure Therapeutics Q2 FY26 net loss narrows to $15.35 million; loss per share improves to $0.31

• OnKure Therapeutics posted a Q2 net loss of $15.35 million, narrowing from $15.39 million a year earlier; loss per share improved to $0.31 from $1.14.
• R&D spending was flat at $12.61 million; G&A costs rose to $4.29 million.
• Cash, cash equivalents and marketable securities climbed to $176.39 million as of June 30, 2026, with runway expected into 2029.
• IND-enabling work continues for PI3Kα pan-mutant selective candidates OKI-345 and OKI-355, with IND submissions planned for 1H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onkure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608041605PRIMZONEFULLFEED9801960) on August 04, 2026, and is solely responsible for the information contained therein.